Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Comment Period Open for FDA Draft Guidance on Osteoporosis Treatments; Plus FDA Rejects Abuse-Deterrent Apadaz

Michele B. Kaufman, PharmD, BCGP  |  June 22, 2016

GENERIC_Drugs_500x270FDA Draft Guidance for Osteoporosis Treatments
The U.S. Food and Drug Administration (FDA) has issued a new draft guidance document for osteoporosis drug development.1 The FDA is asking that, in addition to performing nonclinical pharmacology and toxicology studies, drug manufacturers conduct long-term, nonclinical bone quality studies for new drugs and biologics for osteoporosis indications. These studies are necessary because of concerns about the long-term adverse effects of pharmaceuticals on bone quality. Additionally, there are no validated and reliable methods for noninvasive bone quality assessment in humans. These studies are needed to determine whether osteoporosis treatments result in poorer bone quality when taken for a long time.

According to the FDA, for most of these pharmaceuticals, manufacturers need to investigate the agent in two different animal species. In the guidance, specific recommendations are made for the indication of postmenopausal osteoporosis, the most commonly treated form of osteoporosis. Some biologics may be exempt from the two species recommendation.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The guidance has been issued for public comment purposes only. Comments and suggestions regarding the draft document should be submitted within 60 days of the publication of the notice in the Federal Register announcing the availability of the draft guidance. Electronic comments should be submitted to www.regulations.gov. Written comments should be sent to the Division of Dockets Management (HFA-305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852. All comments should be identified with the docket number (HFA-305) listed in the notice of availability that publishes in the Federal Register.

Immediate-Release Benzhydrocodone Rejected by FDA
An abuse-deterrent, immediate-release, fixed-dose combination of benzhydrocodone (a hydrocodone prodrug and benzoic acid) plus acetaminophen (Apadaz, KP201/APAP) submitted to the FDA for approval to treat short-term acute pain has received a complete response letter.2 In the letter, the FDA states that the benzhydrocodone/acetaminophen (Apadaz) treatment is not ready for approval in its current form.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In May, the FDA’s Anesthetic and Analgesic Drug Products and Risk Management Advisory Committees voted 16–4 to approve the agent, but voted 18–2 that the analgesic should not have abuse deterrent labeling.3 The manufacturer plans to meet with the FDA to discuss future options for the agent.


Michele B. Kaufman, PharmD, CGP, RPh, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

  1. U.S. Food and Drug Administration. Osteoporosis: Nonclinical evaluation of drugs intended for treatment—guidance for industry (draft guidance). 2016 Jun 13.
  2. KemPharm Inc. News release: FDA issues complete response letter for Apadaz new drug application. 2016 Jun 13.
  3. Staff. FDA rejects KemPharm’s Apadaz. BioCentury. 2016 Jun 13.

Page: 1 2 | Multi-Page
Share: 

Filed under:AnalgesicsConditionsDrug UpdatesOsteoarthritis and Bone DisordersPain Syndromes Tagged with:Benzhydrocodone hydrochlorideChronic painFDAFood and Drug AdministrationGuidelinesOsteoporosispostmenopauseRegulation

Related Articles

    FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval

    March 7, 2018

    After reviewing a 10-year study, the FDA cautions that prescribing clarithromycin to patients with heart disease increases the risk of heart problems or death…

    Build Up Bone

    June 1, 2007

    Current management of osteoporosis

    FDA Restricts Use of Systemic Fluoroquinolones Due to Side Effects & Will Review Application of Apadaz for Pain

    June 1, 2016

    The FDA has issued new safety guidelines for systemic fluoroquinolones, restricting their use to patients with no alternative treatment options…

    A Duet of Bone and the Immune System

    July 12, 2011

    Examining emerging perspectives in osteoimmunology

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences